Employees: 319
Size Sinotherapeutics (688247.SS) is a China Health Care company (Biotechnology) with a market value of $494M, the 3724th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.42 on 18 Nov 2026.
Performance Over six months the shares fell 19.3%, against -5.6% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 18 in its peer set.
Growth Revenue fell 17.2% over the last twelve months (peer median -1.5%); the operating margin is -0.2% (peer median -13.1%).
Valuation It trades at 6.2× enterprise value to sales against a peer median of 7.5× (6th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.8 points below its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥398M | CN¥446M | CN¥511M | CN¥300M | CN¥248M |
| Revenue growth | — | -13% | +71% | +21% | — |
| Gross profit | CN¥168M | CN¥159M | CN¥251M | CN¥154M | CN¥158M |
| EBITDA | n/a | CN¥66.7M | CN¥144M | CN¥66.7M | CN¥85.3M |
| Net income | CN¥18.1M | CN¥47.5M | CN¥128M | CN¥61.1M | CN¥92.9M |
| Free cash flow | CN¥88.7M | CN¥63.4M | CN¥46.3M | -CN¥10.2M | -CN¥96.3M |
| Capital expenditure | CN¥26.2M | CN¥41.6M | CN¥94.9M | CN¥39.0M | CN¥176M |
| Total debt | CN¥38,667 | CN¥22,551 | CN¥6,393 | CN¥85,103 | CN¥1.52M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688247.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.0% | -10.2% | 8th lowest of 21 |
| 6-month return | -19.3% | -5.6% | 7th lowest of 18 |
| Distance from 52-week high | -35.2% | -46.1% | 7th highest of 21 |
| Revenue growth (TTM) | -17.2% | -1.5% | 5th lowest of 14 |
| Operating margin | -0.2% | -13.1% | 6th highest of 14 |
| EV / Sales | 6.2× | 7.5× | 6th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | 29.4% | 14.3% | 2nd most demanding of 4 |
| Growth delivered (Del g) | +7.0% | +15.4% | 2nd lowest of 4 |
| Hurdle (Req g minus delivered) | +22.4 pp | -1.5 pp | most demanding of 4 |
| ROIC minus cost of capital | -1.8 pp | -5.7 pp | 2nd highest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | 6.2× | 29.4% | +7.0% |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 5.2× | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | 8,281.1× | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 7.5× | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | 13.3× | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | 3.9× | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | 22.7× | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | 6.2× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 6.4× | 58.8% | +204.7% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 2.0× | 5.0% | +6.5% |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 509.6× | n/a | n/a |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | 11.8× | n/a | n/a |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | 84.4× | n/a | n/a |
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 2.3× | 14.3% | +15.4% |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |